Corneal Onlay Devices and Methods
    2.
    发明申请
    Corneal Onlay Devices and Methods 有权
    角膜镶嵌装置及方法

    公开(公告)号:US20110208300A1

    公开(公告)日:2011-08-25

    申请号:US12897131

    申请日:2010-10-04

    IPC分类号: A61F2/14

    摘要: A corneal only is configured to adhere to the cornea so as to inhibit epithelial growth under the onlay. Structures can be provided on the onlay to adhere the onlay to the eye. At least one of an epithelial layer or the water inhibiting layer can be provided on or over the onlay, for example a natural epithelial layer or water inhibiting layer that inhibits, for example minimizes, water penetration into the onlay, so as to adhere the onlay to the eye with pumping of the endothelium. The water inhibiting layer may comprise a therapeutic covering positioned over the onlay to inhibit swelling of the cornea. The posterior surface of the onlay may be shaped so as to fit the anterior exposed surface of the cornea.

    摘要翻译: 角膜仅被配置成粘附在角膜上,以便抑制覆盖物下的上皮生长。 可以在镶嵌上提供结构以将贴面粘附到眼睛上。 上皮层或水分抑制层中的至少一个可以设置在覆盖物上或上方,例如天然上皮层或水分抑制层,其抑制例如使水渗入到镶嵌物中的最小程度,以便粘附该覆盖层 通过泵送内皮到眼睛。 防水层可以包括定位在覆层上的治疗覆盖物,以抑制角膜的肿胀。 垫片的后表面可以被成形为适合角膜的前暴露表面。

    Method of correcting vision using corneal onlays
    6.
    发明授权
    Method of correcting vision using corneal onlays 有权
    使用角膜镶嵌矫正视力的方法

    公开(公告)号:US09125735B2

    公开(公告)日:2015-09-08

    申请号:US12897131

    申请日:2010-10-04

    IPC分类号: A61F2/14 A61F9/00

    摘要: A corneal onlay is configured to adhere to the cornea so as to inhibit epithelial growth under the onlay. Structures can be provided on the onlay to adhere the onlay to the eye. At least one of an epithelial layer or the water inhibiting layer can be provided on or over the onlay, for example a natural epithelial layer or water inhibiting layer that inhibits, for example minimizes, water penetration into the onlay, so as to adhere the onlay to the eye with pumping of the endothelium. The water inhibiting layer may comprise a therapeutic covering positioned over the onlay to inhibit swelling of the cornea. The posterior surface of the onlay may be shaped so as to fit the anterior exposed surface of the cornea.

    摘要翻译: 角膜镶嵌被配置成粘附在角膜上,以便抑制覆盖物下的上皮生长。 可以在镶嵌上提供结构以将贴面粘附到眼睛上。 上皮层或水分抑制层中的至少一个可以设置在覆盖物上或上方,例如天然上皮层或水分抑制层,其抑制例如使水渗入到镶嵌物中的最小程度,以便粘附该覆盖层 通过泵送内皮到眼睛。 防水层可以包括定位在覆层上的治疗覆盖物,以抑制角膜的肿胀。 垫片的后表面可以被成形为适合角膜的前暴露表面。

    OCULAR INSERT APPARATUS AND METHODS
    9.
    发明申请
    OCULAR INSERT APPARATUS AND METHODS 有权
    OCULAR插入装置和方法

    公开(公告)号:US20130144128A1

    公开(公告)日:2013-06-06

    申请号:US13618052

    申请日:2012-09-14

    IPC分类号: A61B17/00

    摘要: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

    摘要翻译: 舒适的插入物包括保持结构,其尺寸适于放置在眼睑下方并且沿着眼睛的上盖和下盖的结膜囊的至少一部分。 保留结构在放置在眼结膜囊中时抵抗偏转,并且当眼睛移动时沿着囊引导插入物。 保持结构可以以许多方式构造以提供对偏转的抵抗力,并且可以包括环箍强度,以便向外推动保持结构并阻止保持结构朝向角膜的移动。 插入件可以沿着结膜囊的偏转而旋转移动,并且可以包括保持结构,该保持结构具有尺寸适合于结膜折叠的横截面尺寸。 插入物可以包含释放机制和治疗剂以释放长期治疗剂的治疗剂量。

    Drug cores for sustained release of therapeutic agents
    10.
    发明申请
    Drug cores for sustained release of therapeutic agents 审中-公开
    用于持续释放治疗剂的药物核心

    公开(公告)号:US20090104243A1

    公开(公告)日:2009-04-23

    申请号:US12231986

    申请日:2008-09-05

    IPC分类号: A61K9/14 A61P27/06

    摘要: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

    摘要翻译: 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体,其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露,并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中,插入体抑制治疗剂的释放,例如具有对治疗剂基本上不可渗透的材料,使得治疗量通过暴露表面释放,从而避免将治疗剂释放到非靶组织 。